Meta AnalysisID 1550
中国地区非铋剂伴同四联疗法根除幽门螺杆菌：随机对照试验的Meta分析
CRD42016032668
To evaluate whether non-bismuth concomitant quadruple therapy is a reasonable choice for H. pylori eradication as a first line therapy in the Chinese region.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1550
- Evidence Id
- 10108
- Core Evidence Id
- 10108
- Source Meta Analysis Id
- 1505
- Herb2 Meta Analysis Id
- HBMA001505
- Crd Id
- CRD42016032668
- Title
- Non-bismuth concomitant quadruple therapy for Helicobacter pylori eradication in the Chinese region: a meta-analysis of randomized controlled trials
- Review Question
- To evaluate whether non-bismuth concomitant quadruple therapy is a reasonable choice for H. pylori eradication as a first line therapy in the Chinese region.
- Study Type Included
- Randomized controlled trials.
- Condition Being Studied
- Helicobacter pylori infection has been proved to be the major cause of chronic gastritis, gastric ulcer, duodenal ulcer, gastric adenocarcinoma, and gastric mucosa-associated lymphoma. Moreover, H. pylori eradication has become the standard and most widely adopted therapy for curing peptic ulcer disease. The optimal treatment for H. pylori eradication, however, is still unknown.
- Participant
- Randomized controlled trials that evaluate the efficacy of non-bismuth concomitant quadruple therapy in H. pylori eradication; studies performed within the region, which consists mostly of Chinese people, including China, Hong Kong, Taiwan and Singapore.
- Animal
- Human Disease Modelled
- Intervention
- Non-bismuth concomitant quadruple therapy.
- Comparator Control
- Sequential therapy and standard triple therapy.
- Main Outcome
- Eradication rate of Helicobacter pylori infection. Measures of effect 4, 6, 8, or 12 weeks after treatment.
- Outcome Measure
- Additional Outcome
- Compliance.
- Study Method
- Keyword
- Amoxicillin; Bismuth; China; Far East; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Singapore; Taiwan; Treatment Outcome
- Contact
- Ka-Wai Tam [email protected]
- Organisational Affiliation
- Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan
- Funding Source
- No funding
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Taiwan
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2015-12-23
- Anticipated Start Date
- 2015-12-09
- Anticipated Completion Date
- 2016-02-09
- Title Cn
- 中国地区非铋剂伴同四联疗法根除幽门螺杆菌：随机对照试验的Meta分析
- Title En
- Non-bismuth concomitant quadruple therapy for Helicobacter pylori eradication in the Chinese region: a meta-analysis of randomized controlled trials
- Bilingual Status
- complete